CLOS
MRNA icon

Compagnie Lombard Odier SCmA’s Moderna MRNA Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.81M Sell
111,582
-14,156
-11% -$732K 0.08% 109
2026
Q1 		$6.39M Sell
125,738
-15,142
-11% -$706K 0.08% 100
2025
Q4 		$4.15M Sell
140,880
-337
-0.2% -$9.16K 0.05% 107
2025
Q3 		$3.65M Buy
141,217
+3,936
+3% +$110K 0.04% 110
2025
Q2 		$3.79M Buy
137,281
+8,090
+6% +$213K 0.05% 103
2025
Q1 		$3.66M Buy
129,191
+8,905
+7% +$316K 0.04% 118
2024
Q4 		$5M Sell
120,286
-8,018
-6% -$383K 0.07% 96
2024
Q3 		$8.57M Sell
128,304
-9,982
-7% -$916K 0.13% 79
2024
Q2 		$16.4M Sell
138,286
-1,049
-0.8% -$133K 0.28% 62
2024
Q1 		$14.8M Buy
139,335
+2,742
+2% +$276K 0.26% 68
2023
Q4 		$13.6M Buy
136,593
+6,616
+5% +$556K 0.25% 74
2023
Q3 		$13.4M Buy
129,977
+8,615
+7% +$961K 0.31% 63
2023
Q2 		$14.7M Sell
121,362
-698
-0.6% -$93.1K 0.41% 49
2023
Q1 		$18.7M Buy
122,060
+1,649
+1% +$272K 0.47% 52
2022
Q4 		$21.6M Buy
120,411
+4,879
+4% +$798K 0.58% 49
2022
Q3 		$13.7M Sell
115,532
-37,754
-25% -$5.73M 0.39% 51
2022
Q2 		$21.9M Buy
153,286
+2,320
+2% +$332K 0.55% 46
2022
Q1 		$26M Buy
150,966
+47,279
+46% +$7.96M 0.55% 49
2021
Q4 		$26.3M Buy
103,687
+14,882
+17% +$4.35M 0.52% 47
2021
Q3 		$34.2M Buy
88,805
+11,361
+15% +$4.19M 0.74% 38
2021
Q2 		$18.2M Sell
77,444
-84,335
-52% -$15.1M 0.4% 51
2021
Q1 		$21.2M Buy
161,779
+137,360
+563% +$19.9M 0.47% 47
2020
Q4 		$2.55M Buy
24,419
+14,730
+152% +$1.49M 0.07% 106
2020
Q3 		$686K Buy
9,689
+4,800
+98% +$335K 0.02% 174
2020
Q2 		$314K Sell
4,889
-4,150
-46% -$227K 0.01% 225
2020
Q1 		$271K Buy
+9,039
New +$208K 0.01% 219

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Compagnie Lombard Odier SCmA's MRNA Position: Q2 2026 in Review

Compagnie Lombard Odier SCmA reduced its Moderna (MRNA) stake by 11% in Q2 2026, selling an estimated $732K and leaving 111,582 shares worth $7.81M. The position accounts for 0.08% of the portfolio, ranked #109.

Compagnie Lombard Odier SCmA first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $34.2M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Compagnie Lombard Odier SCmA held 111,582 shares of Moderna worth $7.81M as of Q2 2026.
  • Compagnie Lombard Odier SCmA sold 14,156 Moderna shares in Q2 2026, an estimated $732K.
  • Moderna made up 0.08% of Compagnie Lombard Odier SCmA's portfolio in Q2 2026, its #109 holding.
  • Compagnie Lombard Odier SCmA first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Compagnie Lombard Odier SCmA's Moderna position peaked at $34.2M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.